undefined undefined
NaN.000
NaN.00%
Galectin Therapeutics press release (NASDAQ:GALT): Q1 GAAP EPS of -$0.19. As of March 31, 2024, the company had $23.6 million of cash and cash equivalents. The company believes it has sufficient cash ...
05-15 20:50
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NAS...
05-13 20:00
The Dow Jones index closed higher by over 250 points on Monday. When insiders p...
04-23 18:53
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - April 15 Vo...
04-13 03:00
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
04-10 00:10
Madrigal Pharmaceuticals (NASDAQ:MDGL) said that its recently approved NASH/MASH drug Rezdiffra is now available in the US through a specialty pharmacy network. Rezdiffra, also known as resmetirom, re...
04-09 22:03
Gainers: Longeveron (LGVN) +66%. Titan Pharmaceuticals (TTNP) +23%. MSP Recovery (LIFW) +19%. Outset Medical (OM) +16%. Palatin Technologies (PTN) +11%. Losers: Zhongchao (ZCMD) -11%. Adial Pharmaceut...
04-08 22:00
国际咨询公司Research Nester称,到2035年,全球非酒精性脂肪性肝炎(NASH)治疗市场预计将达到483亿美元。
03-18 09:00
Galectin Therapeutics (NASDAQ:GALT) reported its Q3 earnings results on Monday,...
2023-11-13 21:50
Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today presented a poster with new and encouraging clinical data, including two
2023-10-23 20:14